Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Vander Cruyssen B, Peene I, Cantaert T et al (2005) Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun Rev 4:768–774

van Boekel MAM, Vossenaar ER, van den Hoogen FHJ, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res Ther 4:87–93

Steiner G, Smolen J (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res Ther 4:S1–S5 (suppl 2)

Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 41:809–814

Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089

Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 42:677–680

Kroot EJA, de Jong BAW, van Leeuwen MA et al (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43:1831–1835

Schellekens GA, Visser H, de Jong BAW et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163

Vencovsky J, Machacek S, Sedova L et al (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430

Meyer O, Labarre C, Dougados M et al (2003) Anticitrullinated protein/peptide antibody assay in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126

van Jaarsveld CH, ter Borg EJ, Jacobs JW et al (1999) The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689–697

Jansen LMA, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 30:1691–1695

Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 62:870–874

Saraux A, Berthelot JM, Devauchelle V et al (2003) Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 30:2535–2539

Quinn MA, Gough AKS, Green MJ et al (2005) Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) Nov 15 (Epub ahead of print)

Kamali S, Gurel-Polat N, Kasapoglu E et al (2005) Anti-CCP and anti-keratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener’s granulomatosis. Clin Rheumatol 24(6):673–676

Helliwell PS, Taylor WJ (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64:ii3–ii8 (suppl II)

Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C (2005) Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 32:511–515

Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N (2005) The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 44(8):1056–1060

Vander Cruyssen B, Hoffman IEA, Zmierczak H et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64:1145–1149

Alenius GM, Berglin E, Rantapaa Dahlqvist S (2005) Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without manifestations of joint inflammation. Ann Rheum Dis Aug 11 (Epub ahead of print)

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

Senerdem N, Gul A, Konice M et al (1999) The use of two different Health Assessment Questionnaires in Turkish rheumatoid arthritis population and assessment of the associations with disability. Clin Rheumatol 18:33–37

Bridges SL Jr (2001) Rheumatoid factor. In: Koopman WJ (ed) Arthritis and allied conditions. Williams and Wilkins, Philadelphia, pp 1223–1244

van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis. Arthritis Rheum 50:709–715

van Gaalen FA, van Aken J, Huizinga TWJ et al (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121

van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949–R958

De Rycke L, Peene I, Hoffman IEA et al (2004) Rheumatoid factor and anti-citrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 63:1587–1593

Goldbach-Mansky R, Lee J, McCoy A et al (2000) Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res Ther 2:236–243

Zeng X, Ai M, Tian X et al (2003) Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 30:1451–1455

McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5 yr prospective study. Rheumatology (Oxford) 42:778–783